Androgen Signaling in CaP with loss of MAP3K7 and CHD1

前列腺癌的特征在于大的基因组重排和缺失。我们发现基因 ERG易位阴性前列腺癌中CHD 1和MAP 3 K7共缺失表现出 功能协同性我们使用了一种新的小鼠前列腺干细胞发育模型， CHD 1和MAP 3 K7的协同丢失促进了具有改变的侵袭性前列腺癌表型， 谱系分化、异常分泌产物、大量核小体、E-钙粘蛋白丢失和 富集神经元和神经内分泌标志物。AR表达的显著改变也是 观察使用多种人类细胞系模型，我们还证明了CHD 1和MAP 3 K7的缺失 促进去势抵抗性前列腺癌。该项目将评估AR改变的下游靶点， 在体外和动物模型中使用功能基因组学研究MAP 3 K7和CHD 1缺失的肿瘤，并评估 这些目标对患者结局的临床影响。这项工作可能会对管理工作产生影响。 最具侵袭性的前列腺癌CHD 1和MAP 3 K7的共缺失发生在10- 15%的原发性肿瘤中。 复发发生在大约50%的共缺失患者中。如果这些缺失发生在原发性肿瘤中 并预测生存率差，男性可以根据MAP 3 K7和CHD 1状态进行分层。的功能 对这种前列腺癌变异的理解可能会在未来产生新的治疗靶向策略。

Prostate cancer is characterized by large genomic rearrangements and deletions. We show that the genes CHD1 and MAP3K7 are co-deleted in ERG translocation negative prostate cancer. To demonstrate a functional cooperativity we used a novel mouse prostate stem cell developmental model and showed that collaborative loss of CHD1 and MAP3K7 promotes an aggressive prostate cancer phenotype with altered lineage differentiation, abnormal secretory products, massive nuclear atypia, loss of E-cadherin and enrichment in neuronal and neuroendocrine markers. Profound alterations in AR expression were also observed. Using multiple human cell line models we also demonstrate that loss of CHD1 and MAP3K7 promotes castrate-resistant prostate cancer. This project will evaluate downstream targets of AR altered in tumors with loss of MAP3K7 and CHD1 using functional genomics in vitro and in animal models and assess the clinical impact of these targets on patient outcome. This work could have impact on the management of the most aggressive prostate cancer. Co-deletion of CHD1 and MAP3K7 occurs in 10-15 % of primary tumors. Relapse occurs in approximately 50% of patients with co-deletion. If these deletions occur in primary tumors and predict poor survival, men could be stratified based on MAP3K7 and CHD1 status. A functional understanding of this variant of prostate cancer could lead to novel therapeutic targeting strategies in the future.